Latest Development Pipeline News

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.

Dexus has announced its 18.0 cents per security distribution for the first half of 2025, alongside robust full-year results that highlight a resilient portfolio and disciplined capital management. The company signals confidence with a steady outlook despite ongoing economic uncertainty.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

X2M Connect Limited reported a $12.1 million loss for FY25, driven by a 43% revenue drop amid a softer South Korean market and the strategic exit from China. Despite cost cuts and improved margins, the company’s adjusted EBITDA loss widened, prompting a $5.4 million capital raise to shore up its balance sheet.

Lifestyle Communities reported a challenging FY25 with a significant statutory loss driven by a VCAT ruling, yet signs of sales recovery and a refreshed strategy offer a path forward.

Lifestyle Communities reported a significant statutory loss for FY25, driven by legal provisions and asset write-downs, yet signs of recovery emerged in the second half with improved sales and cash flow.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.

GemLife Communities Group has reported a robust first half of FY25, exceeding its prospectus forecasts across revenue, earnings, and home settlements, while reaffirming full-year guidance backed by a recent $750 million IPO.

GemLife Communities Group has reported a strong first half of FY25, exceeding Prospectus forecasts with higher home settlements and premium sales, while confirming full-year guidance. The company’s extensive development pipeline and commitment to sustainability initiatives position it well for continued growth in the Australian Land Lease Community sector.